Stenzl, Arnulf and Penkoff, Hannes and Dajc-Sommerer, Elfriede and Zumbraegel, Andreas and Hoeltl, Lorenz and Scholz, Michael and Riedl, Claus and Bugelnig, Josef and Hobisch, Alfred and Burger, Maximilian and Mikuz, Gregor and Pichlmeier, Uwe (2011) Detection and Clinical Outcome of Urinary Bladder Cancer With 5-Aminolevulinic Acid-Induced Fluorescence Cystoscopy A Multicenter Randomized, Double-Blind, Placebo-Controlled Trial. CANCER, 117 (5). pp. 938-947. ISSN 0008-543X, 1097-0142
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: The medical community lacks results from prospective controlled multicenter studies of the diagnostic efficacy of 5-aminolevulinic acid (5-ALA) cystoscopy on tumor recurrence in patients with superficial bladder tumors. METHODS: A prospective randomized, double-blind, placebo-controlled study was conducted in 370 patients with nonmuscle-invasive urinary bladder carcinoma who received either 5-ALA (n = 187) or a placebo (n = 183) intra-vesically before cystoscopy. Each group underwent cystoscopy under visible white light and under fluorescent light followed by transurethral tumor resection. The primary study objective was to evaluate the 12-month recurrence-free survival. RESULTS: Slightly more patients with tumors were detected by using 5-ALA than by using the placebo (88.5% vs 84.7%). The mean numbers of tumor specimens per patient were 1.8 (5-ALA) and 1.6 (placebo). Intrapatient comparison of fluorescent light versus white light cystoscopy in patients randomized to receive 5-ALA showed a higher tumor detection rate with fluorescent light than with white light cystoscopy. In patients receiving 5-ALA cystoscopy, the percentage of lesions that would not have been detected in these patients by white light cystoscopy ranged between 10.9% (pT1) and 55.9% (atypia). Progression-free survival was 89.4% (5-ALA) and 89.0% (placebo) (P=.9101), and recurrence-free survival 12 months after tumor resection was 64.0% (5-ALA) and 72.8% (placebo) (P=.2216). CONCLUSIONS: In comparison to the placebo, 5-ALA cystoscopy did not increase the rates of recurrence-free or progression-free survival 12 months after tumor resection. Although more tumors per patient were detected in the 5-ALA group, the higher detection rate did not translate into differences in long-term outcome. Cancer 2011;117:938-47. (C) 2010 American Cancer Society
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | TRANSITIONAL-CELL CARCINOMA; TRANSURETHRAL RESECTION; INTRAVESICAL INSTILLATION; UROTHELIAL CARCINOMA; RECURRENCE; DIAGNOSIS; RISK; GUIDELINES; SOCIETY; TERM; urinary bladder; carcinoma; fluorescence; cystoscopy |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 25 Jun 2020 07:52 |
| Last Modified: | 25 Jun 2020 07:52 |
| URI: | https://pred.uni-regensburg.de/id/eprint/21231 |
Actions (login required)
 |
View Item |
